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ABSTRACT
Objectives: To prospectively determine the nature and
rate of adverse drug reactions (ADRs) in children on
antiepileptic drugs (AEDs) and to prospectively evaluate
the effect of AEDs on behaviour.
Setting: A single centre prospective observational study.
Participants: Children (<18 years old) receiving one or
more AEDs for epilepsy, at each clinically determined
follow-up visit.
Primary and secondary outcomes: Primary outcome
was adverse reactions of AEDs. Behavioural and cognitive
functions were secondary outcomes.
Results: 180 children were recruited. Sodium valproate
and carbamazepine were the most frequently used AEDs.
A total of 114 ADRs were recorded in 56 of these
children (31%). 135 children (75%) were on
monotherapy. 27 of the 45 children (60%) on
polytherapy had ADRs; while 29 (21%) of those on
monotherapy had ADRs. The risk of ADRs was
significantly lower in patients receiving monotherapy than
polytherapy (RR: 0.61, 95% CI 0.47 to 0.79, p<0.0001).
Behavioural problems and somnolence were the most
common ADRs. 23 children had to discontinue their AED
due to an ADR.
Conclusions: Behavioural problems and somnolence
were the most common ADRs. Polytherapy significantly
increases the likelihood of ADRs in children.
Trail registration number: EudraCT (2007-
000565-37).
INTRODUCTION
Adverse drug reactions (ADRs) are a major
clinical problem in both paediatric and
adult medicine. Systematic reviews and meta-
analyses of prospective studies of drug surveil-
lance in children have showed that one in 10
children in hospital will experience an ADR.1 2
Studies in the community suggest that at least
one in every 500 children will experience an
ADR each year.3 The actual number is likely to
be greater than this as the majority of ADRs
are unrecognised and unreported.
In 1988, it was identiﬁed that the majority
of children who receive an antiepileptic drug
(AED) as an outpatient will experience an
ADR.4 Since then, however, a signiﬁcant
number of newer AEDs have been intro-
duced, each with their own new ADR proﬁle.
In a large study of fatal suspected ADRs in the
UK, AEDs were the group of medicines most
likely to be associated with a fatality.5 Studies
in the USA have also suggested that AEDs are
associated with a signiﬁcant number of
ADRs.6 There are signiﬁcant ADRs in associ-
ation with the newer AEDs.7 Additionally, the
reporting of drug toxicity in clinical trials of
AEDs is poor.8
Children with epilepsy have a higher inci-
dence of behavioural problems than other
children.9 Moreover, both old and new gener-
ation AEDs have cognitive and behavioural
effects, which can be positive or negative. The
cognitive and behavioural effects of AEDs
have been previously described.10–12 However,
these psychotropic effects are difﬁcult to
ascertain because the presence of seizure
itself could alter mood and behaviour.13
The aims of the study were to prospectively
determine the nature and rate of ADRs in
children on AEDs and to prospectively evalu-
ate the effect of AEDs on behaviour and cog-
nitive function in children with epilepsy prior
to, during and after treatment with AEDs.
METHODS
Study design and patient recruitment
This was a prospective observational study con-
ducted between 2008 and 2011 at Derbyshire
Children’s Hospital. Children aged <18 years,
attending outpatient clinics, and who were
receiving one or more AEDs for any type of
Strengths and limitations of this study
▪ A prospective study of adverse drug reactions to
all antiepileptic drugs used in a single centre.
▪ Cognition and behaviour were assessed using
standardised tools.
▪ The planned sample size was not reached.
▪ Both monotherapy and polytherapy were assessed
for drug toxicity.
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epilepsy were considered suitable for the study. Parents of
the children were approached for consent, either at an
outpatient appointment or during an inpatient stay.
Patients eligible for the study were considered for three
possible groups. Children who were already receiving
AEDs were recruited to group A—prospective surveil-
lance only. At each clinically determined follow-up
appointment, parents and the child were asked about any
possible side effects. Details of the AED treatment, doses,
seizures, etc. were recorded at each visit. Patients starting
AED therapy for the ﬁrst time (group B) had measure-
ments of behaviour and cognitive function performed
prior to starting treatment and 12 months after starting
treatment (table 1). Patients who had been seizure free
for a period of 12 months (group C) had measurements
of behaviour and cognitive function performed while
receiving AED therapy. Those who remained seizure free
for a further period of 12 months and for whom the clin-
ician in charge of the patient had decided to wean off
AED therapy had further assessments 3 months after
treatment was stopped, that is, at 18 months.
Behaviour and cognitive function monitoring
Assessments of behaviour and cognitive function were
performed by a clinical psychologist in subgroups B and
C. Behavioural problems were quantiﬁed by using the
Child Behaviour Checklist (CBCL); the Teacher Report
Form (TRF), for children aged 5 years and over; and the
Youth Self-Report Form (YSRF), for young people aged
11 years and older. Permission was obtained from the
copyright holder to use the CBCL, TRF and YSRF for
this study. Child Behaviour Checklists were available for
the two age groups: 1.5–5 years and 6–18 years. If the
child crossed between these age groups during the
course of the study (ie, from 5 to 6 years), the same age-
speciﬁc CBCL which was used during the ﬁrst visit was
then used for subsequent visits. The CBCL, TRF and
YSRF have been used extensively in studies of behav-
ioural problems in children.14–16 Concern, however, was
raised that some of the items measured in the CBCL
were ambiguous in relation to children treated with epi-
lepsy.15 In view of this ambiguity, the CBCL was cor-
rected for epilepsy-related item ambiguity as illustrated
by workers in the Netherlands.16
Children were asked to complete an assessment of
cognitive functioning. The Wechsler Intelligence Scale
for Children (WISC-IV) was used to assess children aged
6–16 years. Children of age 4–6 years were tested
using the Wechsler Preschool and Primary Scale of
Intelligence Third Edition (WPPSI-III). The tests were
performed at study entry and at 12 months for group B,
and at study entry and 18 months for group C (table 1).
Definition of terms and causality assessment
Causal relationship between ADR and treatment was
assessed by a researcher, with the Naranjo Algorithm17
and by a paediatric clinical pharmacologist based on
clinical judgement. This ensured standardised assess-
ment of suspected ADRs in relation to severity and likeli-
hood. On the Naranjo algorithm, a score of >9 suggests
a deﬁnite attribution to the drug; 5 to 8 indicates a prob-
able cause, 1 to 4 for possible relationship and doubtful
association if the score is <0. Using clinical judgement,
all suspected ADRs were also classiﬁed as: Deﬁnite—dir-
ectly attributable to a drug by having a clear temporal
relationship to drug administration and conﬁrmed by
laboratory investigation, for example, abnormal blood
values; Probable—occurring with a clear temporal rela-
tionship to drug administration and improving on with-
drawal of treatment; Possible—some temporal
relationship to drug administration but the effects could
have been due to the basic or intercurrent illness or
doubtful, if there was no relationship with the drug.
These methods have previously been used in paediatric
ADR surveillance studies.3 18–21
The severity of ADRs was classiﬁed as: Severe—fatal or
potentially life threatening; Moderate—requiring treat-
ment or prolonging the length of stay in hospital; Mild
—no treatment required and no effect on length of stay
in hospital.3 18
Sample size and statistical analysis
The planned sample size was 300–400 children with epi-
lepsy, with at least 50 children in groups B and C to
observe 7 IQ points difference from baseline (100 IQ
Points) to follow-up, with statistical power 80% and sig-
niﬁcant level of 0.05. Statistical analysis was mainly
descriptive. Fisher’s Exact Test was used to compare the
relative risk of ADRs in patients on monotherapy or poly-
therapy. Cognitive and behavioural scores for children in
groups B and C were compared during and after treat-
ment using Wilcoxon Signed Rank Test. Statistical analysis
was performed using SPSS v21 at signiﬁcant level of 0.05.
RESULTS
Study characteristics
A total of 180 children were recruited into this study.
A total of 141 children made up group A, 27 children
were in group B and 12 children group C. The targeted
sample size could not be reached over the course of the
Table 1 Categories of patients recruited into the study
Group Patients Intervention
A All patients on
AEDs
Prospectively look for ADRs
B Newly diagnosed
(starting treatment)
0, 3* and 12 months
C Seizure free for
12 months
0 and 18 months (assuming
no further seizures and
3 months weaning off AEDs)
*Behavioural tests only.
AEDs, antiepileptic drugs; ADRs, adverse drug reactions.
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study. The median age of the patients was 11.2 years
(IQR: 6.9–14.0).
A total of 135 children were on monotherapy and 45
on polytherapy. Over half of the children received either
valproic acid or carbamazepine as monotherapy.
Seventy-four per cent of all AED prescriptions were old
generation drugs. The most frequently prescribed drugs
were sodium valproate (33%), carbamazepine (25%),
lamotrigine (13%) and levetiracetam (7%; table 2).
Adverse drug reactions
A total of 114 ADRs were recorded in 56 of the 180
patients (31%). Twenty-seven of the 45 patients (60%)
on polytherapy experienced ADRs. In contrast, 29 of the
135 children (21%) on monotherapy experienced
ADRs. The risk of ADRs was signiﬁcantly lower in
patients receiving monotherapy than those in polyther-
apy (RR: 0.61, 95% CI 0.47 to 0.79, p<0.0001; ﬁgure 1).
The majority of the ADRs occurred with the two most
widely used AEDs—valproic acid and carbamazepine.
The most common ADRs were behavioural problems
and somnolence (table 3). These accounted for approxi-
mately one-third of all ADRs. Rash was the third most
common ADR, and was most common with carbamaze-
pine and lamotrigine.
AEDs were discontinued in 23 children (table 4).
Dose was reduced in 20 patients. Approximately one in
10 children receiving valproic acid, carbamazepine and
lamotrigine had to stop treatment due to toxicity.
Behavioural problems were the most frequent reason
cited for valproic acid, and rash for both carbamazepine
and lamotrigine. All three children receiving phenytoin
had to stop treatment for a variety of ADRs.
All but four ADRs were considered either probable
or possible by both the Naranjo algorithm and the
paediatric clinical pharmacologist. The majority were
considered probable (57% Naranjo and 79% by the
paediatric clinical pharmacologist). Most ADRs were
moderate (61%) with three severe. The three severe
ADRs were Steven Johnson syndrome (2) and respira-
tory arrest.
Cognitive and behaviour functioning assessment
On the Wechsler IQ scale, the median IQ score when
on treatment was not signiﬁcantly different from the
score off treatment (p=0.411). Although there was a
marginal increase in median score on the behaviour
checklist and impact of epilepsy scale, these differences
were not signiﬁcant (p=0.354 and 0.550, respectively).
Similarly, there was no signiﬁcant difference in the score
during treatment and post-treatment on the youth
report form (p=0.838; table 5).
DISCUSSION
About one-third of patients receiving AEDs in this study
developed at least one ADR during treatment.
Carbamazepine, valproic acid and lamotrigine were the
most frequently prescribed AEDs. A similar AED preva-
lence pattern has been reported in other studies.22–24
Table 2 Number (%) of patients receiving different AED regimen
Drug Monotherapy (%) Polytherapy (%) Total (%)
Sodium valproate 50 (28) 26 (14) 76 (42)
Carbamazepine 50 (28) 8 (4) 58 (32)
Lamotrigine 18 (10) 12 (7) 30 (17)
Levetiracetam 2 (1) 15 (8) 17 (9)
Clobazam 0 14 (8) 14 (8)
Phenobarbitone 6 (3) 6 (3) 12 (7)
Topiramate 3 (2) 9 (5) 12 (7)
Ethosuximide 6 (3) 0 6 (3)
Phenytoin 0 3 (2) 3 (2)
Oxcarbazepine 0 1 (0.5) 1 (0.5)
Gabapentin 0 1 (0.5) 1 (0.5)
Clonazepam 0 1 (0.5) 1 (0.5)
Nitrazepam 0 1 (0.5) 1 (0.5)
AED, antiepileptic drugs.
Figure 1 Percentage of patients on antiepileptic drugs
monotherapy and polytherapy experiencing adverse drug
reactions (ADRs).
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These were also the most common causes of ADRs. The
risk of treatment discontinuation was 1 in 10 patients for
these three AEDs, with rash being the most common
cause for carbamazepine and lamotrigine discontinuation.
Others have shown similar discontinuation rates due to
toxicity in children from carbamazepine and valproic
acid;25 and carbamazepine and phenobarbital.26 Most
AEDs are similar in efﬁcacy but differ in safety.27 A large
Chinese study had reported that similar proportions of
children on carbamazepine, topiramate and valproic
acid had adequate seizure control, while signiﬁcantly
more carbamazepine-treated children had treatment dis-
continuation due to ADRs, mainly rash.27 Han Chinese
population, however, have a genetic predisposition to
carbamazepine-induced rash.28 Carbamazepine is
therefore not recommended as ﬁrst-line treatment in Han
Chinese without genotyping.
Most children in this study received monotherapy,
with only 25% receiving polytherapy. Monotherapy for
epilepsy became standard management in the 1970s as
it was recognised that polytherapy was more likely to be
associated with drug toxicity.29 AED used as monother-
apy is effective in 60–70% of children.25 27 30 Additional
drugs in refractory patients have been shown to be only
marginally beneﬁcial.31 32 Polytherapy is associated with
a greater risk of drug toxicity in paediatric patients in
general,18 33 especially those receiving AEDs.34 More
children receiving polytherapy in this study developed
ADRs, with up to a threefold higher incidence of ADRs
compared to monotherapy. Unfortunately, most new
Table 3 Adverse reactions to antiepileptic drugs
ADR VPA CBZ LTG Others Total
Psychiatry
Behavioural problems 8 7 3 TPM (1), PHT (1), LEV (2) 22
Depression 1 1 – – 2
Anxiety – 1 – – 1
Skin and appendage
Rash – 5 3 PBT (1) 9
Steven-Johnson syndrome PBT (1), PHT (1) 2
Hair loss 4 – – – 4
Metabolic
Increased appetite 2 1 – – 3
Reduced appetite – 1 – – 1
Weight gain 1 1 – – 2
Polydipsia 1 – – – 1
Nervous system
Somnolence/sleep disorders 2 6 2 CLB (4), ETX (1), PBT (1), PHT (1), LEV (1) 18
Headache 2 – 2 – 4
Fatigue 2 2 – – 4
Dizziness – 1 2 – 3
Blurred vision – 3 – – 3
Poor concentration – – – TPM (1), LEV (1) 2
Auditory hallucination 1 – – – 1
Tremor 1 – – – 1
Paraesthesia – – – TPM (1) 1
Dystonia – – – PHT (2) 2
Increased/new seizure – – – TPM (1), OXC (1) 2
Gastrointestinal
Nausea 2 2 – ETX (1) 5
Vomiting 1 2 1 4
Abdominal pain 1 – 1 TPM (1) 3
Diarrhoea – – 1 – 1
Others
Fever – 1 – – 1
Enuresis 1 – – TPM (1) 2
Incontinence – 1 – – 1
Renal stone – – – TPM (1) 1
Respiratory arrest – – – Paraldehyde (1) 1
Thrombocytopenia/bruising 3 – – LEV (1) 4
Elevated ALT 1 – – – 1
Gum hypertrophy 1 PHT (1) 2
Total 34 36 15 29 114
ALT, alanine transaminase; ADRs, adverse drug reactions; CBZ, carbamazepine; CLB, clobazam; ETX, ethosuximide; LEV, levetiracetam;
LTG, lamotrigine; OXC, oxcarbazepine; PBT, phenobarbital; PHT, phenytoin; TPM, topiramate; VPA, valproic acid.
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AEDs are tested by the pharmaceutical companies as
add-on therapy and drug toxicity is poorly described in
these studies.8 This encourages clinicians to use poly-
therapy in epilepsy.
Since several of the AEDs share similar pharmacokinetic
pathways, enzyme induction or inhibition may be a major
problem with some drug combinations.35 One such com-
bination is valproic acid and lamotrigine. Valproic acid
inhibits lamotrigine glucuronidation, thereby increasing
its plasma concentration and toxicity.36 37 AEDs also share
similar pharmacodynamic mechanisms, which may have
additive effects and increase the likelihood of ADRs. The
use of AED combinations with different mechanisms of
action has been advocated.35
There have been few pharmacovigilance studies of
AEDs in children.4 38–40 The main ADRs identiﬁed in this
study were behavioural problems (12%) and somno-
lence/sleep problems (10%). These were also the two
most common ADRs in a previous study more than
20 years ago.4 Another study in India with a different
AED utilisation pattern reported a lower incidence of
behavioural effects (5.7%).38 While valproic acid and
carbamazepine were the most commonly prescribed
AEDs in this study, about two-third of the patients in the
Indian study received phenytoin. We have reported no
signiﬁcant differences in cognitive and behavioural func-
tions during and after AED treatment. A limitation of this
study is the insufﬁcient number of patients recruited.
Much larger studies are required to adequately deter-
mine behavioural effects of AEDs. In addition, causality
was assessed using the Naranjo algorithm, which is not
paediatric speciﬁc. There is no paediatric speciﬁc tool to
assess causality.
In conclusion, polytherapy increases the possibility of
ADRs in children. Physicians should give AED polyther-
apy only when the maximum therapeutic doses of
monotherapy are ineffective. Both clinicians and
parents should monitor AED treated children for
adverse reactions, especially behavioural problems and
somnolence.
Table 4 Treatment discontinuation due to adverse reactions
Drug Adverse reaction Patients (N)
Valproic acid Behavioural problems 2
Tiredness 1
Nausea, vomiting, abdominal pain 1
Hyperactivity, behavioural problems, tremor 1
Mood swing 1
Auditory hallucination 1
Total 7
Carbamazepine Rash 4
Nausea ,vomiting, reduced appetite, incontinence,
behavioural problems
1
Gum hypertrophy 1
Total 6
Lamotrigine Rash 2
Dizziness, sleep disturbance, abdominal pain 1
Total 3
Phenytoin Steven-Johnson syndrome* 1
Dystonia, aggression, increased seizure 1
Gum hypertrophy, drowsiness 1
Total 3
Phenobarbital Steven-Johnson syndrome* 1
Levetiracetam Nose bleed 1
Oxcarbazepine Aggravated seizure 1
Paraldehyde Respiratory arrest* 1
Total 23
*Severe ADRs.
ADRs, adverse drug reactions.
Table 5 Cognitive and behavioural scores for children in groups B and C during and after treatment
Method (no of children) Median score on treatment (IQR) Median score off treatment (IQR) p Value
Full scale IQ (n=26) 90 (86–103) 91 (83–105) 0.411
Child behaviour checklist (n=26) 23 (13–41) 25 (13–52) 0.354
Impact of epilepsy scale (n=27) 20 (16–27) 23 (14–28) 0.550
Youth report form (n=10) 41 (13–65) 32 (13–62) 0.838
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